What are the indications, dosage, and contraindications for using tenecteplase in acute massive pulmonary embolism?

Tenecteplase in Pulmonary Embolism

Tenecteplase is indicated for massive (high-risk) pulmonary embolism with hemodynamic instability, administered as a weight-adjusted single IV bolus, but is NOT FDA-approved for PE and carries significant bleeding risk that may exceed alteplase.

Indications

High-Risk (Massive) PE - Clear Indication

• Administer systemic thrombolytic therapy to patients with high-risk PE 1
• High-risk PE is defined by hemodynamic instability: shock (systolic BP <90 mmHg) or persistent hypotension requiring vasopressor support 2, 1
• Tenecteplase has demonstrated efficacy in cardiac arrest due to massive PE, with successful ROSC achieved even after prolonged CPR (45+ minutes) 3, 4

Intermediate-Risk (Submassive) PE - Controversial

• Do not routinely administer systemic thrombolysis as primary treatment in patients with intermediate- or low-risk PE 1
• However, tenecteplase may reduce right ventricular dysfunction in hemodynamically stable patients with RV dilation (reduction in RV/LV ratio of 0.31 vs 0.10 with placebo at 24 hours, p=0.04) 5
• Consider only for patients with "clinical evidence of adverse prognosis (new hemodynamic instability, worsening respiratory failure, severe RV dysfunction, or major myocardial necrosis)" 2

Low-Risk PE - Contraindicated

• Thrombolysis is not recommended 2, 1

Dosage

Standard Weight-Based Dosing

Weight-adjusted single IV bolus (extrapolated from STEMI dosing, as tenecteplase is NOT FDA-approved for PE) 6:

• <60 kg: 30 mg
• 60-69 kg: 35 mg
• 70-79 kg: 40 mg
• 80-89 kg: 45 mg
• ≥90 kg: 50 mg

Reduced-Dose Regimens (Emerging Evidence)

• Half-dose tenecteplase (0.37 mg/kg or ~17.5 mg) has been used successfully in high-risk elderly patients (>90 years) with hemodynamic compromise 7
• Critical caveat: A 2025 study found 17% bleeding rate with tenecteplase vs 5% with alteplase in massive PE, raising safety concerns 8

Administration

• Single IV bolus over 5-10 seconds 6
• Follow immediately with unfractionated heparin (UFH) without delay 1
• UFH dosing: 70 IU/kg bolus, then maintain aPTT 1.5-2.5x control or activated clotting time ≥250 seconds 2

Contraindications

Absolute Contraindications (from FDA label for STEMI, apply to PE) 6:

• Active internal bleeding
• History of cerebrovascular accident
• Intracranial or intraspinal surgery or trauma within 2 months
• Intracranial neoplasm, arteriovenous malformation, or aneurysm
• Known bleeding diathesis
• Severe uncontrolled hypertension

Relative Contraindications:

• Recent major surgery or trauma
• Recent GI/GU bleeding
• Recent puncture of non-compressible vessels
• Pregnancy (though life-sustaining therapy should not be withheld) 6

Critical Safety Considerations

Bleeding Risk - Major Concern

The most recent 2025 data suggests tenecteplase may have HIGHER bleeding rates than alteplase in massive PE 8:

• Major bleeding: 17% with tenecteplase vs 5% with alteplase
• One symptomatic intracranial hemorrhage occurred with tenecteplase
• Two patients required massive transfusion protocol

However, another 2025 study found no difference in bleeding (12% vs 13.8%) or major bleeding (8% vs 6.9%) 9, highlighting conflicting evidence.

Mortality Considerations

• In-hospital mortality remains high (75-83%) in massive PE regardless of thrombolytic choice 8, 9
• Rescue thrombolytic therapy should be administered to patients with hemodynamic deterioration on anticoagulation alone 1

Alternative Interventions

If thrombolysis is contraindicated or fails 2, 1:

1. Surgical pulmonary embolectomy (Class IIa recommendation)
2. Catheter-directed embolectomy/fragmentation (Class IIa recommendation)
3. Transfer to advanced PE center if these services unavailable locally

Common Pitfalls

1. Using tenecteplase off-label: Remember this is NOT FDA-approved for PE; all PE use is extrapolated from STEMI data 6
2. Delaying anticoagulation: Start UFH immediately, even before thrombolytic administration 1
3. Inappropriate use in intermediate-risk PE: The bleeding risk may outweigh benefits in hemodynamically stable patients 1, 8
4. Inadequate monitoring: Establish invasive arterial access for hemodynamic monitoring in shock/hypotension 2
5. Wrong dosing: Tenecteplase is weight-based; protocol deviations occur in 3-4% of cases 9

Algorithm for Decision-Making

Step 1: Assess hemodynamic status

• Shock/persistent hypotension → High-risk PE → Thrombolysis indicated
• Stable BP but RV dysfunction → Intermediate-risk PE → Thrombolysis NOT routinely recommended
• Stable BP, no RV dysfunction → Low-risk PE → Anticoagulation only

Step 2: If high-risk PE, assess contraindications

• Absolute contraindications present → Consider catheter/surgical embolectomy
• No contraindications → Administer weight-based tenecteplase bolus + UFH

Step 3: Monitor for response and complications

• Hemodynamic improvement expected within 1-14 hours 7
• If deterioration occurs → Rescue intervention (repeat thrombolysis, catheter/surgical embolectomy)
• Monitor closely for bleeding complications